Sterilization Container Monitoring: FDA's New Class II Rule

If you manufacture, distribute, or use rigid sterilization containers with built-in electronic monitoring, the FDA just moved the compliance goalposts. On June 1, 2026, the agency published a final order in the Federal Register (Document No. 2026-10908) classifying this device type into Class II (special controls) under 21 CFR Part 880. What this means practically: a 510(k) premarket notification is now the price of admission, and a codified set of special controls now defines what "adequate performance" looks like for these devices.

The lesson here isn't limited to sterilization containers. It's a pattern worth understanding. FDA regularly uses the classification process to resolve regulatory ambiguity when a new technology emerges inside an established device category, and when a new classification drops, manufacturers who assumed they were operating in a gray zone suddenly have a very clear answer — and a compliance clock that's already running.

What This Device Actually Is

A rigid sterilization container with electronic monitoring is exactly what it sounds like: a hard-sided container used to hold and protect surgical instruments through a sterilization cycle, with an integrated electronic system that monitors and records cycle parameters. The electronic component might track temperature, pressure, exposure time, or sterilization cycle data — and in more advanced versions, may include RFID integration, digital indicators, or data logging for traceability purposes.

Traditional rigid sterilization containers have been around for decades and are already classified as Class II under 21 CFR 880.6860. The electronic monitoring variant is being classified as its own device type because the integrated electronics create a distinct risk profile that the existing classification didn't fully address.

This matters because sterile processing failures are not a theoretical risk. The CDC estimates that on any given day, approximately 1 in 31 hospitalized patients has at least one healthcare-associated infection (HAI). Surgical site infections — the second most common HAI — account for roughly 157,000 cases annually in the United States and add an average of $20,785 in costs per affected patient. When sterilization fails, patients pay for it. Electronic monitoring exists to catch those failures before instruments reach the operating room, which is why FDA has a real interest in ensuring the monitoring actually works.

The Classification Order: What Changed

Before this order, manufacturers of sterilization containers with electronic monitoring occupied an ambiguous position. The device combined elements of an established Class II product (the container itself) with electronic components that didn't fit neatly into any existing product code. Some manufacturers filed 510(k)s voluntarily; others didn't.

The June 1, 2026 final order resolves that ambiguity. FDA is classifying the rigid sterilization container with electronic monitoring under 21 CFR Part 880 as a Class II device subject to special controls. The product code assigned to this device type will be part of the codified regulatory language going forward.

FDA has determined that classifying the rigid sterilization container with electronic monitoring into Class II — rather than Class III — provides a reasonable assurance of safety and effectiveness, provided manufacturers comply with the applicable special controls now codified in the final order.

Class II with special controls means:

• A 510(k) premarket notification is required before marketing (no exemption has been indicated)
• Manufacturers must demonstrate compliance with the special controls identified in the order
• General controls — 21 CFR Part 820 quality system requirements, labeling, registration, and listing — continue to apply in full
• No PMA is required; the special controls are considered sufficient to manage the residual risk

Special Controls: What You Now Need to Demonstrate

Special controls are FDA's mechanism for addressing residual risks that general controls alone can't handle. For this device type, the special controls address the unique performance and safety risks introduced by the electronic monitoring components. The areas the order targets fall into several interconnected performance categories.

Here's a practical comparison of what changes under the new classification:

If you were relying on general controls and common industry standards to self-certify compliance, you now have a codified checklist to work against — which is actually more useful, even if it creates more immediate work.

The 510(k) Pathway: Your Predicate Question

For most manufacturers, the immediate question is: what do I use as a predicate? A 510(k) requires demonstrating substantial equivalence to a legally marketed predicate device, and the predicate needs to share the same intended use and have the same or similar technological characteristics.

Here's how I'd think about this:

If you have an existing cleared sterilization container, you can likely use your own previously cleared device (without electronic monitoring) as a predicate for the container itself, then address the electronic monitoring component separately — either through the new classification's substantial equivalence criteria or by pointing to cleared electronic monitoring systems in adjacent device categories.

If you're new to market, you'll need to identify a predicate from existing cleared devices in the sterilization container space. The FDA's 510(k) database is searchable by product code, and the newly established product code for this device type will become the natural landing zone.

If you're currently marketing a device without a 510(k), this order creates a mandatory compliance obligation. You cannot continue to market the device without going through the 510(k) process. FDA has not announced an explicit grace period for devices already in commerce, which means the transition window is not unlimited.

One practical note on predicates: the electronic monitoring component is the novel element here. Be prepared to provide performance testing data that directly addresses the monitoring function — not just the container's physical attributes.

Practical Compliance Roadmap

Here's how I'd sequence the work if I were advising a manufacturer right now:

Step 1: Determine whether you're affected. Does your device include integrated electronic monitoring — sensors, data logging, digital indicators, RFID, or similar functionality built into the container system? If yes, this classification order applies to you. If your container relies only on external chemical or biological indicators, you likely fall under the existing 21 CFR 880.6860 classification and this order doesn't create a new obligation.

Step 2: Audit your technical file. Pull together everything you have — design documentation, verification and validation testing, risk management files under ISO 14971, software documentation if applicable, and biocompatibility data. Match what you have against the special controls in the classification order. The gaps in that audit become your pre-submission work list.

Step 3: Determine your 510(k) strategy. Identify your predicate, prepare your substantial equivalence argument, and decide whether a pre-submission (Q-Sub) meeting with FDA is worth pursuing. For a device with novel electronic features, a Q-Sub is often worth the 60-day wait — it can prevent a much longer review cycle if FDA comes back with questions you could have answered upfront.

Step 4: Address the software component separately. If your electronic monitoring system includes software, FDA will expect documentation aligned with their software guidance — the level of concern framework, hazard analysis, verification and validation testing. Don't treat this as an afterthought. Software issues are one of the most common reasons 510(k)s come back with additional information requests.

Step 5: Review and update your quality system. Your ISO 13485 QMS or 21 CFR Part 820 quality system needs to reflect the current classification. Update your device classification documentation, your design history file, and your post-market surveillance plan to account for the new classification and special controls.

For a deeper look at aligning your ISO 13485 documentation to FDA special controls requirements, see our guide to bridging ISO 13485 and FDA 510(k) requirements.

Effective Dates and What Happens Next

The final order was published June 1, 2026. Under FDA's standard process for classification orders, the classification and special controls take effect upon publication. There is no delayed effective date announced in the order.

What this means in practice:

• New devices going to market need a 510(k) clearance before marketing. No ambiguity here.
• Devices currently in commerce exist in a more complicated position. FDA has authority to take enforcement action, but historically the agency works with manufacturers who are making good-faith progress toward compliance. "Good faith" needs to be documented, though — a written plan, a timeline, and active forward movement are far more defensible than a phone call you made once.
• The special controls are codified regulatory text, not guidance. That means they're enforceable, and they set the minimum bar for what you need to demonstrate in your 510(k).

I'd recommend treating September 1, 2026 as a self-imposed internal deadline to complete your initial gap assessment and have a pre-submission plan in place. That's not an FDA deadline — it's a practical one that keeps you ahead of enforcement exposure.

Why This Classification Makes Sense

Some manufacturers will read this order as FDA adding bureaucratic friction to devices that have been working fine in the field. I understand that frustration, but I think it misses what the electronic monitoring component actually introduces.

A traditional rigid sterilization container fails in physical ways you can see — a broken latch, a damaged filter, visible contamination. An electronic monitoring system can fail in ways that are invisible — a sensor that reports a successful cycle when the temperature profile was actually inadequate, software that logs data incorrectly, an indicator that doesn't update when a cycle is aborted. Those failures are harder to catch through visual inspection or biological indicators alone.

The electronic monitoring component introduces a software-driven failure mode that traditional sterilization container controls cannot address — which is precisely why FDA determined that special controls, rather than general controls alone, are necessary to provide reasonable assurance of safety and effectiveness.

The 510(k) pathway with special controls is FDA's way of saying: show us evidence that the monitoring actually works before patients' lives depend on it. That's a reasonable ask.

What ISO 13485 Manufacturers Should Know

If your quality management system is certified to ISO 13485, you already have much of the infrastructure this classification requires. ISO 13485 Section 7.3 covers design and development, Section 7.5.1.1 addresses validation of processes (including sterilization processes), and Section 4.1.6 requires documented software validation for software used in medical devices.

The gap for most ISO 13485-certified manufacturers isn't the QMS structure — it's making sure the technical content exists. A well-structured QMS that doesn't contain a complete design history file for the electronic monitoring system, or that lacks software documentation at the appropriate level of concern, won't survive a 510(k) review.

One practical tip: if you're approaching ISO 13485 recertification around the same time you're working through the 510(k), align the work. Your notified body and FDA are looking at much of the same underlying documentation. Running both processes simultaneously, with the same documentation, is more efficient than treating them as separate projects.

You can find a breakdown of post-market surveillance requirements for Class II devices in our ISO 13485 post-market surveillance overview.

Post-Market Obligations Don't End at Clearance

Classification into Class II doesn't end your obligations when the 510(k) clears. The special controls likely include post-market requirements — adverse event reporting under 21 CFR Part 803, complaint handling, and potentially post-market performance testing or surveillance. When you build your post-market surveillance plan (required under ISO 13485 Section 8.2.1 and FDA's quality system regulations), make sure it specifically addresses the electronic monitoring component.

For a device whose entire purpose is to catch sterilization failures, post-market surveillance data about monitoring failures is critical. If your electronic system is generating false positives or missing failed cycles in real-world use, you want to know that before FDA does.

Manufacturers currently marketing rigid sterilization containers with electronic monitoring without a 510(k) clearance are subject to enforcement action under 21 U.S.C. § 331, which prohibits introduction of an unapproved Class II device into interstate commerce. Warning Letters, import alerts, and injunctions are all available FDA remedies — and the liability exposure from a sterilization failure tied to an uncleared device extends well beyond a regulatory fine.

The classification order is the starting line. Whether you're a manufacturer who's been waiting for regulatory clarity or one who didn't realize you needed it, the path forward is the same: audit your technical file, identify your predicate, engage FDA early, and document every step of your compliance effort.

Last updated: 2026-07-22